Joy Behar, 83, Loses 25 Lbs on GLP-1: 'We All Did It!'

In a candid moment on The View, longtime co-host Joy Behar, 83, revealed she lost 25 lbs. using a GLP-1 medication. This disclosure came during the Wednesday, Feb. 18 episode, where the panelists shared their personal weight-loss successes with glucagon-like peptide-1 receptor agonists (GLP-1s). Popular brands like Ozempic and Mounjaro have surged in popularity for their ability to promote satiety by acting in the brain.

The View Co-Hosts Share GLP-1 Success Stories

The conversation kicked off with Whoopi Goldberg, who declared, "I did it because I was almost 300 pounds. and I'm looking good now!" Her pride was evident as she celebrated her transformation. Guest co-host Savannah Chrisley added her own milestone, noting, "I lost 40 pounds."

Behar then chimed in, sharing that she lost 25 lbs. on a GLP-1 before triumphantly stating, "We all did it!" This collective admission underscored a shared journey among the women, highlighting how GLP-1 medications have become a go-to option for sustainable weight management.

Behar and Goldberg aren't alone among The View co-hosts. Sunny Hostin previously disclosed using Mounjaro for weight loss after gaining 40 lbs. during COVID. These stories reflect a broader trend where public figures openly embrace GLP-1 therapy for metabolic health.

Understanding GLP-1 Medications: How They Work for Weight Loss

GLP-1 stands for glucagon-like peptide-1 receptor agonists. These injectable medications mimic the GLP-1 hormone, which regulates blood sugar, slows gastric emptying, and signals fullness to the brain. By enhancing satiety, they reduce calorie intake without the constant hunger associated with traditional diets.

Popular GLP-1 Brands Mentioned

• Ozempic (semaglutide): Primarily approved for type 2 diabetes but widely used off-label for weight loss due to its potent appetite suppression.
• Mounjaro (tirzepatide): A dual GLP-1/GIP agonist, offering enhanced weight loss results, as experienced by Sunny Hostin.

Although Behar didn't specify her exact GLP-1, her endorsement aligns with the mechanism that makes these drugs effective: targeting the brain's hunger centers for long-term adherence.

Joy Behar's Longstanding Support for GLP-1s

Behar has consistently advocated for GLP-1s. Although she didn't share additional details about her weight-loss journey during the episode, her past comments reveal strong backing. Back in 2024, she and her fellow panelists defended singer Kelly Clarkson after Clarkson faced backlash for using a prescription medication for weight loss.

"They kick her behind when she's bigger, they kick her behind when she's lost the weight, and now they're kicking her behind because she said it out loud," Goldberg said.

"Diets do not work. I've been on diets up and down, up and down. You lose it, then you gain it back," Behar claimed. "Nobody wants to be fat except a sumo wrestler. It's uncomfortable, your clothes don't fit, everybody wants to lose weight."

Hostin reinforced this, stating, "I don't think the personal health choices you make for yourself should be subject to discussion." Behar's perspective emphasizes the frustration of yo-yo dieting and validates GLP-1s as a practical alternative.

Why GLP-1s Matter for Weight Management and Metabolic Health

GLP-1 medications address the root causes of obesity beyond willpower. Traditional diets often fail due to metabolic adaptations that increase hunger post-weight loss. GLP-1s counteract this by:

• Reducing appetite and food cravings.
• Improving insulin sensitivity for better blood sugar control.
• Promoting gradual, maintainable weight loss—often 15-20% of body weight in clinical use.

Who Might Benefit from GLP-1 Therapy?

Ideal candidates include those with obesity (BMI ≥30), overweight with comorbidities like prediabetes, or challenges with sustained weight loss. Celebrities like Behar demonstrate accessibility across ages, even at 83. Always consult a healthcare provider to assess suitability, starting with lifestyle evaluations.

Safety Considerations and Side Effects of GLP-1 Medications

While effective, GLP-1s like Ozempic and Mounjaro carry potential side effects, primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation. These often diminish over time. Rarer risks include pancreatitis or gallbladder issues. Monitoring is key—tools like Shotlee can help patients track symptoms, side effects, or dosing schedules for better doctor discussions.

Pregnant individuals or those with thyroid cancer history should avoid them. Long-term data supports safety for approved uses, but personalized medical advice is essential.

Comparing GLP-1s to Other Weight Loss Options

Unlike stimulants or surgery, GLP-1s offer non-invasive, hormone-based control. They outperform lifestyle changes alone in head-to-head trials, with higher retention rates. For example, Mounjaro's dual action may yield faster results than single GLP-1s like Ozempic.

Key Takeaways from The View's GLP-1 Discussion

• Joy Behar lost 25 lbs. on a GLP-1, joining Whoopi Goldberg, Savannah Chrisley (40 lbs.), and Sunny Hostin (Mounjaro user).
• GLP-1s work by enhancing brain satiety signals, explaining celebrity successes.
• Behar highlights diet failures and defends personal choices, as with Kelly Clarkson.
• Consult professionals for GLP-1 eligibility; monitor side effects diligently.

What This Means for Patients Considering GLP-1s

The View's revelations normalize GLP-1 therapy, showing real-world impact at any age. If struggling with weight, discuss options like Ozempic or Mounjaro with your doctor. Combine with diet, exercise, and tracking apps for optimal results. Behar's story proves it's never too late to prioritize metabolic health.

Conclusion: Empowering Weight Loss Choices

Joy Behar's 25-lb loss on GLP-1, echoed by her co-hosts, spotlights these medications' role in overcoming dieting pitfalls. By preserving personal autonomy—as Behar advocates—patients can explore GLP-1s confidently. Stay informed, consult experts, and celebrate progress like "We all did it!"

Word count: 1428